- Home
- PHUN vs CRVO Comparison
PHUN vs CRVO Comparison
Compare PHUN & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | CRVO |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 35.9M |
| IPO Year | 2016 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PHUN | CRVO |
|---|---|---|
| Price | $2.04 | $3.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.25 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 131.6K | 60.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,883,000.00 | $4,006,510.00 |
| Revenue This Year | $89.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.57 | N/A |
| 52 Week Low | $1.56 | $2.82 |
| 52 Week High | $3.88 | $13.13 |
Technical Indicators
Market Signals| Indicator | PHUN | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 37.72 |
| Support Level | $1.79 | $2.82 |
| Resistance Level | $2.28 | $4.27 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 42.11 | 24.89 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.